Cardiac toxicity with monoclonal antibodies therapy
Keywords: cancer therapy, monoclonal antibodies, cardiac toxicity, pericardial effusion
AbstractBreast cancers which overexpress the human epidermal growth factor receptor 2 (HER2) proteins generally have poor prognosis. Trastuzumab is a monoclonal antibody which inhibits HER-2 activation and has been shown to be an effective therapy for women with breast cancers that overexpress HER2 proteins. The most important side effect of trastuzumab is cardiotoxicity. We report a patient with left ventricular dysfunction and pericardial effusion after treatment with pertuzumab and trastuzumab.
Download data is not yet available.
How to Cite
Mazek, H., Verma, R., & Wischmeyer, J. (2015). Cardiac toxicity with monoclonal antibodies therapy. The Southwest Respiratory and Critical Care Chronicles, 3(11), 52-54. Retrieved from https://pulmonarychronicles.com/index.php/pulmonarychronicles/article/view/221
All articles are published under the Creative Commons Attribution-Non-Commercial License https://creativecommons.org/licenses/by-sa/2.0/